Silexion Therapeutics Corp SLXNW
Set alert
As of Oct 30, 3:34 PM ET
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.032
- Prev close
- 0.0057
- Mkt cap
- 3.20K
- Vol
- 17.05K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0043
- High
- 0.0092
- Forward P/E
- 0.00
- Beta
- -0.11
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.01
- EPS (TTM)
- 0.00
- Beta
- -0.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -305.63K
- Total cash
- 2.78M
- Total debt
- 144.00K
- Return on equity
- -116.66%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Silexion Therapeutics Corp
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- silexion.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on SLXNW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 12.52% | 743,475 | 18.51K | Sep 29, 2024 |
| Linden Advisors LP | 5.68% | 337,500 | 8.40K | Sep 29, 2024 |
| Aristeia Capital, LLC | 4.08% | 242,174 | 6.03K | Sep 29, 2024 |
| Hartree Partners, LP | 3.16% | 187,500 | 4.67K | Sep 29, 2024 |
| SECURITY BENEFIT LIFE INSURANCE CO | 2.53% | 150,000 | 3.73K | Sep 29, 2024 |
| Clear Street LLC | 2.31% | 137,037 | 3.41K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RiverNorth Capital & Income Fund, Inc. | 0.09% | 5,298 | 131 | Sep 29, 2024 |
| RiverNorth Opportunities Fd | 0.04% | 2,547 | 63 | Sep 29, 2024 |
| First Tr Exchange Traded Fd-First Trust Alternative Opportunities Fd | 0.00% | 142 | 3 | Sep 29, 2024 |